MAKENA
Total Payments
$4.8M
Transactions
23,713
Doctors
9,599
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $11,046 | 11 | 4 |
| 2022 | $275,834 | 42 | 19 |
| 2021 | $73,293 | 224 | 200 |
| 2020 | $93,679 | 504 | 453 |
| 2019 | $1.4M | 1,712 | 1,135 |
| 2018 | $948,860 | 9,529 | 5,796 |
| 2017 | $2.0M | 11,691 | 6,328 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1M | 79 | 64.9% |
| Consulting Fee | $572,750 | 469 | 11.8% |
| Education | $340,967 | 21,714 | 7.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $335,000 | 145 | 6.9% |
| Grant | $202,054 | 11 | 4.2% |
| Travel and Lodging | $85,123 | 410 | 1.8% |
| Honoraria | $63,500 | 18 | 1.3% |
| Food and Beverage | $58,550 | 833 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $39,855 | 34 | 0.8% |
Payments by Type
Research
$3.1M
79 transactions
General
$1.7M
23,634 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HPC to reduce PTB in HIV-positive women in Zambia | AMAG Pharmaceuticals, Inc. | $1.1M | 0 |
| A MULTI-CENTER, RANDOMIZED, OPEN- LABEL STUDY COMPARING BIOAVAILABILITY WHEN PRESERVATIVE-FREE HYDROXYPROGESTERONE CAPROATE MAKENA IS ADMINISTERED AS A 1 ML TRAMUSCULAR IM INJECTION OR AS A XML SUBCUTANEOUS SC AUTO-INJECTION IN HEALTHY POST-MENOPAUSAL WOMEN | AMAG Pharmaceuticals, Inc. | $769,016 | 0 |
| Improving Pregnancy Outcomes with Progesterone - 2 IPOP-2 a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy | AMAG Pharmaceuticals, Inc. | $441,297 | 0 |
| IMPROVING PREGNANCY OUTCOMES WITH PROGESTERONE - 2 IPOP-2 A TRIAL OF 17-HYDROXYPROGESTERONE CAPROATE TO REDUCE PRETERM BIRTH AMONG WOMEN RECEIVING ANTIRETROVIRAL THERAPY IN PREGNANCY | AMAG Pharmaceuticals, Inc. | $218,385 | 0 |
| A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MGML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPONTANEOUS PRETERM DELIVERY | AMAG Pharmaceuticals, Inc. | $129,621 | 3 |
| 17 HYDROXYPROGESTERONE CAPROATE SUPPLEMENTATION A NOVEL THERAPEUTIC FOR THE MANAGEMENT OF PREECLAMPSIA | AMAG Pharmaceuticals, Inc. | $99,274 | 0 |
| The relationship of cervicovaginal microbiome to local inflammation, cervical length shortening, and ultrasound-indicated cerclage success | AMAG Pharmaceuticals, Inc. | $75,000 | 0 |
| The role of micro-RNA 223 in the pathogenesis of preeclampsia through interference with the epithelial-to-mesenchymal FBXW7 and Notchl-dependent transition of the extravillous trophoblast | AMAG Pharmaceuticals, Inc. | $75,000 | 0 |
| Metformin for Prevention of Hypertensive Disorders of Pregnancy in Women with Type 1 Diabetes Mellitus | AMAG Pharmaceuticals, Inc. | $52,890 | 0 |
| A Comparison of Intramuscular and Subcutaneous Administration of 17-hydroxyprogesterone Caproate (17-OHPC) in Pregnancy | AMAG Pharmaceuticals, Inc. | $49,036 | 0 |
| Implementing a Pilot Program of Universal Cervical Length through Virtual Education and outreach to address Disparities in Preterm Birth | AMAG Pharmaceuticals, Inc. | $24,903 | 0 |
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension | AMAG Pharmaceuticals, Inc. | $24,834 | 0 |
| THE IMPACT OF MOMS2B ON PERINATIONAL OUTCOMES IN FRANKLIN COUNTY, OHIO | AMAG Pharmaceuticals, Inc. | $23,638 | 0 |
| IMPACT OF HIGHER DOSE ON THE PARMACOKINETICS | AMAG Pharmaceuticals, Inc. | $17,799 | 1 |
| A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena Hydroxyprogesterone Caproate Injection, 250 mgmL When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women | AMAG Pharmaceuticals, Inc. | $15,522 | 2 |
| Antenatal Corticosteroids (ACS) and Educational Performance | AMAG Pharmaceuticals, Inc. | $10,380 | 0 |
| Promoting Screening and Adherence to Aspirin for Preeclampsia Prevention | AMAG Pharmaceuticals, Inc. | $2,500 | 0 |
Top Doctors Receiving Payments for MAKENA — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Specialist | Barstow, CA | $208.20 | 2 |
| , M.D | Obstetrics & Gynecology | Easton, PA | $207.23 | 12 |
| , M.D | Maternal & Fetal Medicine | Greenville, SC | $207.04 | 17 |
| , M.D | Obstetrics & Gynecology | Dallas, TX | $206.05 | 13 |
| , M.D | Obstetrics & Gynecology | Hialeah, FL | $205.73 | 10 |
| , M.D | Obstetrics & Gynecology | Encinitas, CA | $204.87 | 21 |
| , MD | Specialist | South Miami, FL | $204.79 | 11 |
| , M.D | Obstetrics & Gynecology | Pasadena, TX | $203.54 | 6 |
| , D.O | Obstetrics & Gynecology | Little Silver, NJ | $202.84 | 13 |
| , D.O | Obstetrics & Gynecology | Allentown, PA | $202.44 | 11 |
| , M.D | Maternal & Fetal Medicine | Chattanooga, TN | $202.20 | 8 |
| , M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $201.77 | 19 |
| , MD | Obstetrics & Gynecology | Chicago, IL | $201.27 | 3 |
| , M.D | Obstetrics & Gynecology | Chicago, IL | $201.27 | 3 |
| , M.D | Obstetrics & Gynecology | Poway, CA | $201.11 | 7 |
| , M.D | Obstetrics & Gynecology | Rochester Hills, MI | $201.05 | 7 |
| , M.D | Obstetrics & Gynecology | Paramount, CA | $201.02 | 7 |
| , M.D | Obstetrics & Gynecology | New York, NY | $200.41 | 19 |
| , D.O | Obstetrics & Gynecology | Southfield, MI | $199.31 | 7 |
| , M.D.,F.A.C.O.G | Obstetrics & Gynecology | Fairfax, VA | $198.24 | 12 |
| , M.D | Obstetrics & Gynecology | Fairfax, VA | $198.24 | 12 |
| , MD | Maternal & Fetal Medicine | Tampa, FL | $196.27 | 3 |
| , MD | Obstetrics & Gynecology | Orland Park, IL | $194.04 | 8 |
| , DO | Obstetrics & Gynecology | Warren, MI | $193.27 | 6 |
| , MD | Obstetrics & Gynecology | New York, NY | $191.42 | 12 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.8M
- Total Doctors 9,599
- Transactions 23,713
About MAKENA
MAKENA is a drug associated with $4.8M in payments to 9,599 healthcare providers, recorded across 23,713 transactions in the CMS Open Payments database. The primary manufacturer is AMAG Pharmaceuticals, Inc..
Payment data is available from 2017 to 2023. In 2023, $11,046 was paid across 11 transactions to 4 doctors.
The most common payment nature for MAKENA is "Unspecified" ($3.1M, 64.9% of total).
MAKENA is associated with 17 research studies, including "HPC to reduce PTB in HIV-positive women in Zambia" ($1.1M).